Skin Fibroblast Network Complexity for Alzheimer's Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing Alzheimer's disease are challenging due to the progressive and multi-factorial nature of the condition, with a need for improved early screening and diagnostic tools that can accurately predict or definitively diagnose AD before symptomatic diagnosis.
Innovation Solution
The use of quantitatively measured complexity of skin-sampled fibroblast networks, where skin fibroblast cells are cultured on Matrigel to form networks that are analyzed for parameters such as integrated score, fractal dimension, lacunarity, and cell migration, allowing for a minimally invasive and potentially more accurate screening for AD.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional diagnostic methods for Alzheimer's disease are used, then diagnostic accuracy can be improved, but the complexity and invasiveness of the testing procedure increases
Solution Approach 1:
The patent uses skin fibroblast cells as a peripheral copy or surrogate of brain tissue to diagnose Alzheimer's disease. Instead of directly analyzing complex brain tissue or performing invasive neurological tests, the method cultures skin-derived fibroblasts and analyzes their network formation patterns, which replicate key pathological features of AD. This copying approach maintains high diagnostic accuracy while significantly reducing procedural complexity and invasiveness.
Solution Approach 2:
The patent introduces skin fibroblast cells as an intermediary between the patient and the diagnostic analysis. These fibroblasts serve as a mediator that reflects brain pathology through their network formation behavior when exposed to beta-amyloid. By analyzing this intermediary tissue rather than directly examining brain tissue or using complex imaging, the method achieves accurate diagnosis with simpler procedures.
2Measurement precision
If traditional diagnostic methods for Alzheimer's disease are used, then diagnostic accuracy can be improved, but the invasiveness of the procedure increases
Solution Approach 1:
The method uses skin fibroblasts as a non-invasive copy of brain tissue for diagnostic purposes. By culturing and analyzing peripheral skin-derived cells rather than performing lumbar punctures, brain biopsies, or other invasive procedures, the patent achieves accurate AD diagnosis while eliminating harmful invasive effects.
Solution Approach 2:
The skin fibroblast cells serve as self-service diagnostic indicators that naturally reflect brain pathology through their network formation patterns. The cells themselves provide the diagnostic information needed without requiring invasive extraction or complex preparation, making the diagnostic process simpler and less invasive while maintaining accuracy.
3Measurement precision
If complex diagnostic procedures are used for early Alzheimer's detection, then diagnostic accuracy improves, but the time and cost required increases
Solution Approach 1:
The patent performs preliminary action by culturing skin fibroblasts in advance and analyzing their network formation patterns before clinical symptoms fully manifest. This allows early detection of Alzheimer's disease through pre-symptomatic changes in fibroblast behavior, enabling earlier intervention while using a relatively quick in vitro assay rather than lengthy complex procedures.
Solution Approach 2:
By using skin fibroblasts as a surrogate system that replicates brain pathology, the method enables rapid early detection without requiring time-consuming neuroimaging or complex cognitive assessments. The copying approach allows diagnostic analysis to be performed on easily obtained peripheral cells, significantly reducing diagnostic time while maintaining early detection accuracy.
Data Source
AI summary
The present disclosure relates to a peripheral diagnostic method for screening Alzheimer's disease in patients based on quantitatively measured complexity of skin-sampled fibroblast networks.